We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
24 result(s) found, displaying 1 to 10
-
Jul-2025Prescription medicine evaluationActive ingredient: axatilimab.
-
Jun-2025Prescription medicine evaluationActive ingredient: retifanlimab.
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Apr-2025Prescription medicine evaluationActive ingredient: tafasitamab.
-
Designation or determinationPriority review
-
Designation or determinationOrphan drug
-
Designation or determinationOrphan drug
-
Designation or determinationOrphan Drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MINJUVI tafasitamab 200 mg powder for solution for infusion 1 vial per carton.